Key Details
Price
$1.19Annual ROE
-730.48%Beta
0.32Events Calendar
Next earnings date:
Mar 18, 2025Recent quarterly earnings:
Nov 14, 2024Recent annual earnings:
Mar 18, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Dec 9, 2020Analyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with rare and challenging diseases, today announced the presentation of data from its ongoing Pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (“NPC1”) at the 21st Annual WOR.
Cyclo Therapeutics, Inc. (CYTH) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.29 per share a year ago.
MILWAUKEE , Aug. 23, 2024 /PRNewswire/ -- Ademi LLP is investigating Cyclo Therapeutics (Nasdaq: CYTH) for possible breaches of fiduciary duty and other violations of law in its transaction with Rafael Holdings. Click here to learn how to join our investigation https://www.ademilaw.com/case/cyclo-therapeutics-inc or call Guri Ademi toll-free at 866-264-3995.
NEW YORK , Aug. 22, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Cyclo Therapeutics, Inc. (Nasdaq: CYTH), relating to its proposed merger with Rafael Holdings, Inc. Under the terms of the agreement, Cyclo common stock will automatically be converted into the right to receive shares of Rafael common stock.
Cyclo Therapeutics, Inc. (CYTH) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.33 per share a year ago.
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced the last patient has been enrolled in the Company's pivotal Phase 3 study (“TransportNPC™”) evaluating Trappsol® Cyclo™ for the treatment of systemic and neurological symptoms of Niemann-Pick Disease.
Cyclo Therapeutics, Inc. (Nasdaq: CYTH), a biotechnology company focused on developing transformative medicines for patients with diseases, announced its financial results for the first quarter of 2024 and gave an update on its business activities, including advancements in patient enrollment for the TransportNPC™ trial.
FAQ
- What is the ticker symbol for Cyclo Therapeutics?
- Does Cyclo Therapeutics pay dividends?
- What sector is Cyclo Therapeutics in?
- What industry is Cyclo Therapeutics in?
- What country is Cyclo Therapeutics based in?
- When did Cyclo Therapeutics go public?
- Is Cyclo Therapeutics in the S&P 500?
- Is Cyclo Therapeutics in the NASDAQ 100?
- Is Cyclo Therapeutics in the Dow Jones?
- When was Cyclo Therapeutics's last earnings report?
- When does Cyclo Therapeutics report earnings?
- Should I buy Cyclo Therapeutics stock now?